Assembly hears AB234 to require Medicaid coverage for cancer screenings including at-home colorectal tests

The Assembly Health & Human Services Committee held a hearing on Assembly Bill 234, legislation that would amend Nevada statute to explicitly require Medicaid coverage of screening for certain cancers and to protect access to all evidence-based colorectal screening methods, including FDA-approved at-home stool tests.

Sponsor Assemblymember Natha Anderson (Assembly District 30) said the bill "is to protect access to cancer screens for Nevada Medicaid beneficiaries and increase access to all evidence-based colorectal cancer screening options to improve screen rates, decrease late stage cancer detection, and ultimately save lives." She asked the committee to align Nevada Revised Statutes with current Medicaid practice and the Patient Protection and Affordable Care Act.

Carrie Harrington, executive director of the Nevada Cancer Coalition, told lawmakers that incorporating at-home options such as fecal immunochemical testing (FIT) and multi-target stool DNA tests (for example, Cologuard) is important for rural and working families who face limited local colonoscopy capacity or difficulty taking time off work. "FDA-approved evidence based at home screening options for colorectal cancer screening has really been an incredible advancement in increasing access to care," Harrington said.

The bill text discussed during the hearing would amend the referenced chapter of state law to add explicit coverage for lung and prostate screening and for "all available colorectal cancer evidence-based methods of screening" for Medicaid beneficiaries. Section 2 of the bill directs the Department of Health and Human Services to obtain any necessary federal waiver or state-plan amendment to secure federal funding to fully provide that coverage.

During testimony, several organizations and clinicians offered support. James Cohen, a recently retired medical oncologist and member of the Nevada Cancer Coalition board, told the committee that early detection substantially reduces treatment costs and morbidity; he cited a personal melanoma treatment example and estimated modern immunotherapy costs as evidence that earlier diagnosis can limit expensive advanced-care treatment.

Representing provider and advocacy groups, witnesses offering support included the Nevada State Medical Association (on the public line), Dignity Health St. Rose Dominican, Professional Firefighters Nevada, Comprehensive Cancer Centers of Nevada, Nevada Oncology Society and the Nevada Public Health Association. Several testified that increased access to screening promotes health equity for rural, low-income and medically underserved populations.

Members asked technical and policy questions: several sought clarification about which screening modalities the bill would require insurers to cover and whether coverage would be tied to U.S. Preventive Services Task Force recommendations. Carrie Harrington and the sponsor said screening choices are typically determined by federal guidance (USPSTF) and by insurer and program practice; Anderson said the bill aims chiefly to bring statute into alignment with current Medicaid coverage and to protect access, and staff indicated the substance of specific test choices may be clarified in regulation or program guidance.

Committee members also asked about fiscal impact. The sponsor said there was no fiscal note available at the hearing but that department discussions on the topic had been underway since at least August of the prior year. The bill's language directs the Department to seek federal matching funds as needed.

No committee vote was recorded at the hearing. The sponsor said she would follow up with requested data, including estimates about lives saved by early detection and potential fiscal impacts. The committee closed the hearing and moved on to other agenda items.

Ending: AB234 drew broad support from clinical and advocacy groups at the hearing; the Department of Health and Human Services will be involved if the bill proceeds, including applying for necessary federal approvals and producing fiscal estimates if requested by the committee.